Concerns & Risks -- 6/10
Mid-pack risk/reward. Positives: China sales exposure is below the 10% threshold (a footprint risk,
not a demand risk), and there are multiple dated near-term catalysts -- Penang breakeven, Syracuse
volume production in H2 2026, book-to-bill 1.41x, and an organic earnings-doubling target for
2025-2027. The offset is valuation: forward P/E sits at the peer average (~53.7x) and EV/EBITDA screens
above peers (~40x vs ~29x), with slightly negative FCF during a capex-heavy cycle removing any cushion.
Full but defensible -- it does not screen as cheap.
Weight: 15%
Forward P/E
~53.7x
At peer avg (~54.7x)
Full, no cushion
EV / EBITDA
~40x
Above peers (~29x)
Premium
China Exposure
Low
Below 10% threshold
Footprint, not demand
FCF
Negative
Capex build to $300-320M
No margin of safety
Valuation -- Primary Metric: Forward P/E
| Metric | FY26 Estimate | Multiple | Peer Avg |
|---|---|---|---|
| P / EPS | $4.05 EPS | ~53.7x | ~54.7x (JBL, FLEX) |
| EV / EBITDA (est.) | ~$575M EBITDA | ~40x | ~29x |
| EV / Sales | $4.00B rev | ~5.8x | — |
Full but defensible -- it does not screen as cheap.
On the primary metric (forward P/E ~53.7x) TTMI sits essentially at the peer average for its
EMS/PCB cohort, though ~2x the broader hardware-industry median. On EV/EBITDA it screens above
peers (~40x vs ~29x), reflecting the heavy in-flight capacity build that is depressing near-term
EBITDA. Multiples are estimates built off consensus and web-sourced peer comps and should be read
as directional, not precise. Forward EBITDA (~$575M) is an internal build, not a sourced consensus
figure.
Key Catalysts
| # | Catalyst | Detail |
|---|---|---|
| 1 | Capacity Ramps | Penang approaching breakeven (Q1'26); Syracuse advanced-PCB volume production H2 2026; Eau Claire 18-24 months to equip. Near-to-medium-term margin/revenue catalysts. |
| 2 | AI / Data-Center Inflection | Data Center & Networking grew +61% YoY in Q1'26 (36% of sales); ~80% of revenue now tied to AI + defense secular demand. |
| 3 | Book-to-Bill 1.41x | Overall book-to-bill 1.41x / 1.65x commercial (Q1'26) -- forward demand signal pointing to continued top-line acceleration. |
| 4 | CapEx Raised to $300-320M | Raised from $240-260M to pull forward capacity -- a catalyst if absorbed, a risk if demand softens. |
| 5 | Earnings-Doubling Target | Management target to double earnings 2025-2027, organic only -- a measurable, near-dated promise from a credible team. |
Regulatory / Political Risk
| # | Risk | Severity | Detail |
|---|---|---|---|
| 1 | Defense Appropriations | MEDIUM | A&D was 40% of Q1'26 sales with a $1.6B program backlog -- exposed to US defense budget/appropriations timing, though a tailwind under current spending. |
| 2 | Capex Absorption | MEDIUM | Entire thesis hinges on absorbing a heavy build cycle into demand that materializes on schedule; Syracuse/Eau Claire slippage or an AI-capex digestion would hit a richly-priced stock. |
| 3 | Tariff / Trade Regime | LOW-MEDIUM | Quantified as manageable -- 3-4% direct imports from China, ~11% material, ~29% equipment; tariff cost largely customer-borne with sourcing/timing offsets. |
| 4 | China Manufacturing Footprint | LOW-MEDIUM | China is a manufacturing location, not a major end-market; a decade of divestiture and a pivot to Malaysia/US, but the presence remains a geopolitical/relocation overhang. |
| 5 | Litigation / Impairment | LOW | No active litigation or guidance-withdrawal red flags; the cleanest negative is a prior $32.6M RF&S goodwill impairment (Q4'24), already absorbed. |
Bull Case
| # | Factor | Detail |
|---|---|---|
| 1 | Secular Demand (~80% AI + Defense) | AI compute + defense with book-to-bill over 1.4x; five consecutive quarters of accelerating revenue and expanding EBITDA validate the trajectory. |
| 2 | Capacity De-Risks China | New US/Malaysia capacity de-risks the China footprint and unlocks higher-margin advanced-PCB work. |
| 3 | Credible Organic Target | CEO Roks framing an organic earnings-doubling target by 2027 -- no M&A dependency, backed by accelerating reported results. |
| 4 | Superior Mix at Peer Multiple | Forward P/E roughly in line with EMS peers despite a superior end-market mix (defense + AI vs commodity EMS). |
Bear Case
| # | Factor | Detail |
|---|---|---|
| 1 | Full Valuation, No Cushion | ~53.7x forward P/E (at peer average but ~2x the hardware median) and ~40x forward EV/EBITDA (above the ~29x peer level) leave no margin of safety. |
| 2 | Negative FCF on Heavy Build | FCF slightly negative on a trailing basis with CapEx raised to $300-320M -- the thesis hinges on the build being absorbed by demand on schedule. |
| 3 | Sub-Scale Price-Taker | Oligopoly gate fails -- TTM is low-single-digit share in fragmented markets and a fast-follower price-taker in its fastest-growing AI segment. |
| 4 | Single-Engine Concentration | The story is increasingly a DC&N/AI story while A&D (40% of revenue) is quietly decelerating (+15% to +11%); trajectory is exposed when the AI comp gets hard. |
| 5 | Thin Coverage, Appropriations Risk | Consensus is thin (3-4 analysts); defense revenue carries appropriations risk and the China manufacturing footprint remains a geopolitical overhang. |
Score Rationale
Score of 6/10 reflects a mid-pack risk/reward. China sales exposure is below the 10% threshold (a clear positive vs the rubric), there are multiple dated near-term catalysts, and regulatory risk is moderate rather than acute. The offset is valuation: the primary forward P/E sits at the peer average (not below it) and EV/EBITDA screens above peers, with slightly negative FCF during a capex-heavy cycle removing any cushion.
What keeps it off a higher score: Forward P/E at peer average and EV/EBITDA above peers -- no discount. Slightly negative FCF removes any margin of safety. Single-engine concentration on DC&N/AI as A&D decelerates. Thin analyst coverage and defense-appropriations exposure.
What prevents a lower score: Low China sales exposure (below the rubric threshold). Multiple dated near-term catalysts (Penang breakeven, Syracuse H2 2026, 1.41x book-to-bill, organic earnings-doubling target). Regulatory/tariff risk quantified as manageable and customer-borne. No active litigation.
Net: low China + real catalysts + at-peer/full valuation + manageable-but-present regulatory and footprint risk lands squarely between the rubric's "5" (mixed) and "10" (clean) anchors -- a 6/10.
Data sourced from Daloopa (company_id 7157, fundamentals) and web-sourced consensus and peer multiples.